Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts

Blood

Volumn 109, Issue 2, 2007, Pages 711-719

  Gajate, Consuelo ^a,b   Mollinedo, Faustino ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EDELFOSINE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; PERIFOSINE; PROCASPASE 8; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; LIPID RAFT; MITOCHONDRION; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RETROVIRUS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 33846243705     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-016824     Document Type: Article

References (51)

1. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc. 2002;77:813-822.
2. Hussein MA, Juturi JV, Lieberman I. Multiple myeloma: present and future. Curr Opin Oncol. 2002;14:31-35.
3. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
4. Bruno B, Giaccone L, Rotta M, Anderson K, Boccadoro M. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia. 2005;19:1729-1738.
5. 3 (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab. 2002;3:491-525.
6. Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents. 2003;3:343-353.
7. 3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem. 2004;11:3163-3184.
8. L. Cancer Res. 1997;57:1320-1328.
9. Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs. 2005;23:279-286.
10. Gajate C, Fonteriz RI, Cabaner C, et al. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer. 2000;85:674-682.
11. Gajate C, Del Canto-Janez E, Acuna AU, et al. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med. 2004;200:353-365.
12. 3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood. 2001;98:3860-3863.
13. Delmas D, Rebe C, Lacour S, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem. 2003;278:41482-41490.
14. Lacour S, Hammann A, Grazide S, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 2004;64:3593-3598.
15. Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem. 2005;280:11641-11647.
16. Mollinedo F, Gajate C. FasL-independent activation of Fas. In: Wajant H, ed. Fas Signaling. Georgetown, TX: Landes Bioscience and Springer Science; 2006:13-27.
17. Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat. 2006;9:51-73.
18. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
19. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10:26-35.
20. Grassme H, Jekle A, Riehle A, et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem. 2001;276:20589-20596.
21. Hueber AO, Bernard AM, Herincs Z, Couzinet A, He HT. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep. 2002;3:190-196.
22. Scheel-Toellner D, Wang K, Singh R, et al. The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem Biophys Res Commun. 2002;297:876-879.
23. Grassme H, Cremesti A, Kolesnick R, Gulbins E. Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene. 2003;22:5457-5470.
24. Varma R, Mayor S. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature. 1998;394:798-801.
25. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31-39.
26. 3: involvement of the Fas receptor/ligand system. Br J Pharmacol. 1999;127:813-825.
27. Diaz-Gonzalez F, Gonzalez-Alvaro I, Campanero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest. 1995;95:1756-1765.
28. Mollinedo F, Burgaleta C, Velasco G, Arroyo AG, Acevedo A, Barasoain I. Enhancement of human neutrophil functions by a monoclonal antibody directed against a 19-kDa antigen. J Immunol. 1992;149:323-330.
29. 3-induced apoptosis of human leukemic cells. Int J Cancer. 2000;86:208-218.
30. Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med. 1999;190:1549-1560.
31. Mollinedo F, Martin-Martin B, Calafat J, Nabokina SM, Lazo PA. Role of vesicle-associated membrane protein-2, through Q-soluble N- ethylmaleimide-sensitive factor attachment protein receptor/R-soluble N-ethylmaleimide-sensitive factor attachment protein receptor interaction, in the exocytosis of specific and tertiary granules of human neutrophils. J Immunol. 2003;170:1034-1042.
32. Gajate C, An F, Mollinedo F. Rapid and selective apoptosis in human leukemic cells induced by aplidine through a Fas/CD95- and mitochondrial- mediated mechanism. Clin Cancer Res. 2003;9:1535-1545.
33. Nieto-Miguel T, Gajate C, Mollinedo F. Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. J Biol Chem. 2006;281:14833-14840.
34. Schon A, Freire E. Thermodynamics of intersubunit interactions in cholera toxin upon binding to the oligosaccharide portion of its cell surface receptor, ganglioside GM1. Biochemistry. 1989;28:5019-5024.
35. Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol. 1998;141:929-942.
36. Christian AE, Haynes MP, Phillips MC, Rothblat GH. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res. 1997;38:2264-2272.
37. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481-490.
38. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501.
39. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem. 1993;268:10932-10937.
40. 3 induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling. Blood. 1999;94:3583-3592.
41. Vrablic AS, Albright CD, Craciunescu CN, Salganik RI, Zeisel SH. Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes. FASEB J. 2001;15:1739-1744.
42. Kharbanda S, Pandey P, Schofield L, et al. Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci U S A. 1997;94:6939-6942.
43. Matzke A, Massing U, Krug HF. Killing tumour cells by alkylphosphocholines: evidence for involvement of CD95. Eur J Cell Biol. 2001;80:1-10.
44. Delmas D, Rebe C, Micheau O, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene. 2004;23:8979-8986.
45. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004;95:777-783.
46. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13:1817-1824.
47. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001;98:795-804.
48. Glasser L, Dalton WS, Fiederlein RL, Cook P, Powis G, Vogler WR. Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid. Exp Hematol. 1996;24:253-257.
49. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053-4062.
50. Berdel WE, Bausert WR, Fink U, Rastetter J, Munder PG. Anti-tumor action of alkyl-lysophospholipids. Anticancer Res. 1981;1:345-352.
51. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. 1999;59:2457-2463.